BioLineRx (BLRX) EBIT Margin (2024 - 2025)
BioLineRx (BLRX) posted EBIT Margin of 1745.36% for Q4 2025, down 237.68% on a QoQ basis from 516.86% in Q3 2025, and down 170769.0% year-over-year from N/an in Q4 2024.
BioLineRx (BLRX) has 2 years of EBIT Margin data on file, last reported at 1745.36% in Q4 2025.
- In Q4 2025, EBIT Margin fell 170769.0% year-over-year to 1745.36%; the TTM figure through Dec 2025 stood at 871.78% (down 80126.0% YoY), while the FY2025 annual figure was 871.78%, down 80126.0% from the prior year.
- EBIT Margin declined to 1745.36% in Q4 2025, from 516.86% in the prior quarter.
- Across five years, EBIT Margin topped out at 37.67% in Q4 2024 and bottomed at 1745.36% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -1,745.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,745.36% |
| Sep 30, 2025 | -516.86% |
| Jun 30, 2025 | -757.57% |
| Mar 31, 2025 | -937.65% |
| Dec 31, 2024 | -37.67% |
| Sep 30, 2024 | -108.98% |
| Jun 30, 2024 | -107.05% |
| Mar 31, 2024 | -70.34% |